Liquid biopsy in lymphoma
In a Hematology-in-Focus session, Dr Davide Rossi (Institute of Oncology Research, Bellinzona, Switzerland) discussed the possibilities and limitations of liquid biopsies in lymphoma. “Circulating tumor DNA can recapitulate the spatial heterogeneity of lymphomas”, said Rossi. Using ultra deep sequencing his group showed that cell free DNA mirrors the genetics of lymphoma cells. Moreover, they were able to detect ibrutinib resistance mutations, and to see clearance of mutations in responding but not in refractory patients.
“CtDNA analysis may inform about the mutations that can be targeted, such as BCR signaling mutations and EZH2 mutations. It can reveal clonal evolution, for identifying mutations causing resistance. It can also be used as a marker to inform response to therapy, and as a new tool for minimal residual disease (MRD) monitoring in lymphoma, where this aspect has never been explored so far.”